Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs ShedRx

By GLP-1 ScorecardUpdated

InvyncibleFactor scores not reassessed.
Site position #270

Lower score

ShedRx
Site position #3

Higher score

Score comparison

ShedRx has the higher recorded score — 87/100 to 63.6/100.

ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shed combines compounded injections and branded Wegovy/Zepbound options with coaching; compare longer-plan supply, fees and guarantee rules before committing.

Before you choose

Before comparing the headline prices, the Invyncible review and the ShedRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Invyncible vs Wholesome Clinic and JumpstartMD vs ShedRx compare each of them with another graded program, and the list of alternatives to Invyncible ranks the programs closest to Invyncible on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueShedRx +39
45
84
Dose & formulationShedRx +18
78
96
Clinical oversightShedRx +14
70
84
Labs & monitoringShedRx +32
52
84
FulfillmentShedRx +15
73
88
Contract termsShedRx +8
77
85
Invyncible · top barShedRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricInvyncibleShedRx
WeighScore63.6/10087/100
GradeCB+
Site position#270#3
Semaglutide$145 starter program; supply length and refill cost need confirmation$199/mo
Tirzepatide$179 per 4-week starter program (2.5 mg weekly, compounded glycine + B12)$299/mo
CoverageVaries by formulation; glycine/B12 programs exclude AR, CA, IN, MN, OR and SCAll 50 states
Brand-name accessYesYes
Oral / sublingualYesYes
Invyncible

Site position #270 · C

Factor scores not reassessed.

Strengths

  • Six pharmacies named with contact details
  • Patients can request a prescription copy or nominate a pharmacy
  • Public catalogs distinguish compounded products, brands and oral options
  • Refills are not automatic; payment is finalized only after physician approval

What to consider

  • Program amounts are not universal monthly prices; dose and formulation can change cost
  • Shipping cost not established on the reviewed program pages
  • State exclusions differ by formulation
  • Compounded medications are not FDA-approved
ShedRx

Site position #3 · B+

Strengths

  • Published injection plans plus other formulation and branded prescribing options
  • One-month injection prices listed at $199 semaglutide / $299 tirzepatide
  • Terms describe monthly coaching and name six possible pharmacy partners

What to consider

  • Six- and twelve-month plans specify 24 and 48 weeks of medication
  • The 120-day promise has first-time-user and participation requirements and does not cancel a longer plan
  • Branded pages display conflicting $99/$125 membership charges, with medication separate
  • Actual clinician/pharmacy assignment and the applicable minimum term need confirmation

Featured provider

ShedRx

ShedRx scores 87/100 (B+). Shed combines compounded injections and branded Wegovy/Zepbound options with coaching; compare longer-plan supply, fees and guarantee rules before committing.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard